Join our daily newsletter At The Bell to receive exclusive market insights
- HonorHealth becomes Artrya’s fifth US commercial customer
- First secured outside foundation customers and Sapphire research programs
- Commercial agreement with recurring and usage-based revenue potential
- Minimum contracted value of US$0.5M for Salix coronary anatomy
Artrya (ASX: AYA) has signed a five-year commercial agreement with major Arizona health system HonorHealth, with a minimum contracted value of US$0.5 million.
Artrya is a medical technology company commercialising its Salix AI-powered cloud platform, for the real time, point of care assessment and management of coronary artery disease globally.
HonorHealth becomes Artrya’s fifth US commercial customer and, importantly, its first inbound customer secured outside the company’s foundation customers and Sapphire study participants.
Co-founder and CEO of Artrya, John Konstantopoulos, said the agreement represents another important milestone, demonstrating growing market awareness of Salix and broadening customer acquisition channels.
“The HonorHealth agreement is another major step forward in our US commercial roll-out and, importantly, represents our first inbound US customer,” Mr Konstantopoulos said.
“Coming shortly after Huntsville Health became our first Sapphire study partner to convert to a commercial customer, it demonstrates growing awareness of Salix and commercial momentum across multiple channels of our US strategy.
“HonorHealth is an exciting customer for Artrya. It is a major US health system with a strong focus on using advanced medical imaging technology to improve clinical workflows and patient care.
“Through its evaluation of Salix, we have already developed a strong relationship with HonorHealth’s clinical and leadership teams and demonstrated the value our platform can bring to its CCTA program.
“The scale of HonorHealth is also significant. With nine acute-care hospitals across Phoenix and Scottsdale providing CCTA, the network provides a meaningful opportunity to demonstrate the scalability and commercial potential of Salix across a large health system.
“Importantly, our shared vision extends beyond the initial deployment of Salix. We see an opportunity to help HonorHealth increase CCTA capacity, embed advanced coronary assessment into routine clinical care and, over time, explore the development of a leading cardiovascular imaging Centre of Excellence in Arizona that could serve as a reference for other US health systems.”
Salix is an AI-powered, cloud-based platform for the non-invasive diagnosis and analysis of coronary artery disease (CAD).
AYA was steady at 0.5¢. Mkt cap $7.055M.
Join the discussion: See what HotCopper users are Atrya now and be part of the conversations that move the markets.
The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
